Core Viewpoint - The company, Yidu Tech (02158.HK), announced a share buyback on October 17, 2023, spending HKD 1.013 million to repurchase 181,000 shares at a price range of HKD 5.56 to 5.65 per share [1] Summary by Category - **Company Actions** - Yidu Tech executed a buyback of 181,000 shares at a total cost of HKD 1.013 million [1] - The repurchase price per share ranged from HKD 5.56 to 5.65 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2025年10月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 第一章節註釋： | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股 ...

重大项目接连中标，彰显专业实力 药物研发助力突破，专业服务获认可 近日，中国AI医疗行业头部企业医渡科技发布《2025年9月通讯》。本月，医渡科技在临床研究服务、 医院人工智能建设、创新药研发支持及健康保险运营等业务板块均取得显著进展。公司在重大项目中 标、AI医疗产品商业化落地及民生健康保障等领域表现突出，展现出多元业务协同发展的良好态势。 在临床研究服务领域，医渡科技成功中标山东衍渡生物科技有限公司"重组人神经生长因子 （SMR001）滴眼液Ⅲ期临床研究项目"，项目总金额约人民币5582万元。同时，在医院人工智能建设 方面，公司中标北京肿瘤医院人工智能建设项目，金额达488万元，标志着公司首个院级大模型应用带 金项目正式落地，为后续大模型业务的全面拓展树立了示范案例。 普惠健康保持续优化，保障民生见实效 在健康保险运营领域，医渡科技作为"北京普惠健康保"主运营平台，积极支持2025年金融教育宣传周专 项活动。截至2025年8月底，"北京普惠健康保"医疗责任和特药责任累计处理理赔案件41.9万件，单笔 最高赔付金额76.11万元，快赔赔付案件量占总赔付案件量89%，切实为北京市民提供了医疗保障。 本月各项业 ...

Summary of Key Points Core Viewpoint - A number of companies, including Xiaomi Group and Kuaishou, conducted share buybacks on October 14, 2025, with Xiaomi leading in terms of buyback amount and quantity [1]. Group 1: Buyback Details - Xiaomi Group-W (01810) repurchased 4 million shares for a total of 195 million, with a year-to-date total of 10.5954 million shares, representing 0.040% of its total share capital [2]. - Kuaishou-W (01024) repurchased 1.3146 million shares for 98.4067 million, with a year-to-date total of 3.4516 million shares, representing 0.081% of its total share capital [2]. - Shoucheng Holdings (00697) repurchased 16.05 million shares for 36.3578 million, with a year-to-date total of 90.146 million shares, representing 1.237% of its total share capital [2]. Group 2: Other Notable Buybacks - Vitasoy International (00345) repurchased 1.3980 million shares for 11.3964 million, with a year-to-date total of 4.25 million shares, representing 0.405% of its total share capital [2]. - IGG (00799) repurchased 150,000 shares for 6.145 million, with a year-to-date total of 17.809 million shares, representing 1.527% of its total share capital [3]. - China Hongqiao (01378) repurchased 300,000 shares for 7.594 million, with a year-to-date total of 154 million shares, representing 1.650% of its total share capital [2].

Core Viewpoint - The company, Yidu Technology (02158.HK), has been actively repurchasing its shares, indicating a strategy to support its stock price amid recent declines [2][3]. Summary by Sections Share Buyback Activity - On October 14, Yidu Technology repurchased 1.4728 million shares at prices ranging from 5.750 to 5.990 HKD, totaling 8.5796 million HKD [2]. - The stock closed at 5.760 HKD on the same day, reflecting a decrease of 4.00%, with a total trading volume of 97.4232 million HKD [2]. - Since October 13, the company has conducted buybacks for two consecutive days, acquiring a total of 2.5036 million shares for a cumulative amount of 14.6717 million HKD, during which the stock price fell by 6.49% [2]. Year-to-Date Buyback Summary - Year-to-date, Yidu Technology has executed four buyback transactions, acquiring a total of 3.1916 million shares for a total expenditure of 18.5980 million HKD [3]. - The detailed buyback transactions are as follows: - October 14: 1.4728 million shares at a maximum price of 5.990 HKD and a minimum price of 5.750 HKD, totaling 8.5796 million HKD [3]. - October 13: 1.0308 million shares at a maximum price of 5.990 HKD and a minimum price of 5.800 HKD, totaling 6.0920 million HKD [3]. - September 29: 0.3350 million shares at a maximum price of 5.790 HKD and a minimum price of 5.670 HKD, totaling 1.9271 million HKD [3]. - September 26: 0.3530 million shares at a maximum price of 5.690 HKD and a minimum price of 5.570 HKD, totaling 1.9992 million HKD [3].

该信息由智通财经网提供 智通财经APP讯，医渡科技(02158)发布公告，该公司于2025年10月14日斥资857.96万港元回购147.28万 股股份，每股回购价格为5.75-5.99港元。 ...

Core Viewpoint - The company, Yidu Technology (02158), has been actively repurchasing its shares, indicating confidence in its stock value and financial health. Additionally, the approval of a new drug for infant vascular tumors highlights the company's role in supporting pharmaceutical development through market research and analysis services [1]. Share Buyback Activity - On October 14, Yidu Technology repurchased 1.4728 million shares at a price range of HKD 5.75 to HKD 5.99 per share, totaling HKD 8.58 million [1]. - Since September 26, the company has conducted four share buybacks, accumulating a total of 3.1916 million shares repurchased, with a total expenditure of HKD 18.6359 million [1]. Drug Approval and Market Support - The company provided critical market research and project analysis services for the recently approved topical treatment, Timolol Maleate Gel, which is the first drug targeting proliferative superficial infantile hemangiomas [1].

Core Viewpoint - Medicure Technology (02158) has been actively repurchasing its shares, indicating confidence in its stock value and future prospects [1] Share Buyback Activity - On October 14, Medicure Technology repurchased 1.4728 million shares at a price range of HKD 5.75 to HKD 5.99, totaling HKD 8.58 million [1] - Since September 26, the company has conducted four share buybacks, accumulating a total of 3.1916 million shares repurchased, with a total expenditure of HKD 18.6359 million [1] Product Development and Market Support - The company has provided critical market research and project analysis services for the recently approved topical treatment for infantile hemangiomas, marking a significant advancement in its product offerings [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2025年10月14日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 ...

Core Insights - Beijing Meisen Pharmaceutical announced the approval of the world's first topical treatment for proliferative superficial infantile hemangiomas, Timolol Maleate Gel, by the National Medical Products Administration (NMPA) on September 30, 2025 [1][2] - The successful launch of Timolol Maleate Gel demonstrates China's capability to transition from imitation to original innovation in the pharmaceutical industry [2] Group 1: Product Development and Approval - Timolol Maleate Gel is designed for the treatment of proliferative superficial infantile hemangiomas, a common pediatric skin condition that can lead to serious complications if not treated early [1] - The gel was developed by Beijing Meisen Pharmaceutical, which conducted a systematic pharmacokinetic study of Timolol in infants aged 28 to 180 days, marking a first in the international arena [1] Group 2: Market Research and Support - Yidu Technology's project consulting and evaluation team provided critical market research and project analysis services, supporting the drug's development and market entry [1] - The team was involved from the early feasibility study to later clinical strategies, ensuring that each step of the project was based on reliable information [1] Group 3: Industry Impact and Collaboration - Yidu Technology has served over 350 pharmaceutical companies, supporting 686 clinical trials and 275 real-world studies, facilitating the approval of multiple innovative drugs [2] - The collaboration between Yidu Technology and Beijing Meisen Pharmaceutical represents a significant milestone in advancing pediatric drug development [2]